Elekta and Merck & Co to create health monitor for RCC
Digital health monitoring firm Elekta has partnered with US pharmaceutical firm Merck & Co to develop patient monitoring for people with renal cell carcinoma (RCC)
The partners will co-develop a digital module for RCC patients, featuring “comprehensive symptom monitoring and patient support”.
Additionally, the module will allow patients to stay connected with their care team, and offer information about their disease, treatment, and possible side effects.
The partners hope to validate the module later this year, in collaboration with “multiple leading cancer clinics in Europe”.
The solution will use Elekta’s Kaiku Health digital platform for patient engagement and reported outcomes monitoring.
“Addressing potential challenges in cancer care involves the implementation of digital patient support,” said Anish Patankar, Senior Vice President and Head of Business Line Software at Elekta. “This initiative aims to provide structured support for symptom management and monitoring while also educating patients about their disease and treatment.”
Merck & Co also trades under the name MSD outside of Canada and the US, to distinguish itself from the similarly named German company, the Merck Group.
The digital health market is forecast to be worth $549.7 billion by 2028 – driven by the growing importance of telemedicine.